title: [Misuse of alcohol and new drug treatments].
abstract: Three drugs are currently marketed in France in the prevention of relapse in alcohol-dependent patients. Their efficacy though real remains limited and it is useful to develop other molecules. Some products are at present under evaluation, and are already or could be used in the near future in the treatment of alcohol dependence: baclofene, oxybate de sodium (GHB), nalmefene, topiramate, ondansetron and aripiprazole. The available studies on these molecules are still limited and the results sometimes clinically modest. Nevertheless, some of them open interesting future prospects. If there is no big revolution to wait in the short term in the treatment of alcohol dependence, we can consider some interesting orientations: better effectiveness on alcohol consumption, but also change of paradigm concerning the objectives and the methods of this treatment: reduction of consumption versus abstinence, treatment on request, choice of the molecule guided by objective criteria (psychosocial, biological, genetic...).
authors.affiliation: Service de médecine L, addictologie, CHU de Nancy, 54000 Nancy. secretariat.pr.paille@chu-nancy.fr
authors.forename: François
authors.initials: F
authors.lastname: Paille
mesh_terms: D000437:Alcoholism / Q000188:drug therapy*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068180:Aripiprazole; D001418:Baclofen / Q000627:therapeutic use; D058786:GABA-B Receptor Agonists / Q000627:therapeutic use; D006801:Humans; D017294:Ondansetron / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D058786:GABA-B Receptor Agonists; D010879:Piperazines; D015363:Quinolones; D012702:Serotonin Antagonists; D017294:Ondansetron; D000068180:Aripiprazole; D001418:Baclofen